US Patent Issued to UNIVERSITY HEALTH NETWORK on June 10 for "Crystal form S4 of the PLK4 inhibitor (1R,2S)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)-1 h-imidazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin-2'-one fumarate" (Canadian Inventors)

ALEXANDRIA, Va., June 18 -- United States Patent no. 12,325,700, issued on June 10, was assigned to UNIVERSITY HEALTH NETWORK (Toronto).

"Crystal form S4 of the PLK4 inhibitor (1R,2S)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)-1 h-imidazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin-2'-one fumarate" was invented by Sze-Wan Li (Toronto) and Mark Robert Bray (Oakville, Canada).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed is Crystal Form S4 of a fumarate salt of compound (I) represented by the following structural formula: (I) The molar ratio between compound (I) and fumaric acid is 1.0:1:0. Crystal Form S4, 5 characterized by an X-ray powder diffraction pattern which comprises peaks...